Generate Biomedicines, Inc.
No SEC Form 4 filings for $GENB in the last 30 days.
Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruit
Nvidia (NVDA) said AI’s “most profound impact” will be in life sciences and announced an AI co-innovation lab with Eli Lilly, targeting up to $1 billion over five years. Nvidia’s May 13F showed it owned 833,000+ shares of Generate Biomedicines (GENB), valued at about $10.4 million as of Q1 end. The article links Nvidia’s AI push to its biotech investment.
Nvidia, through its venture arm NVentures, owns 833,325 shares of Generate Biomedicines (NASDAQ: GENB), according to the article. The stake totals about $13 million, and Generate Biomedicines is a pre-profit biotech developing an AI platform for virtual drug testing; four candidates are in its pipeline, including one in Phase 3 for severe asthma (GB-0895). The piece cites estimates that drug development can take 10–15 years and about $2.6 billion per approved medicine.
Over the past 7 days, alphai's AI scored 1 news story mentioning GENB (Generate Biomedicines, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent GENB coverage spans financial news, earnings and technology.
Clinical execution and cash runway updates are the key tradable elements, with near-term catalysts tied to ERS/ESMO poster presentations and ongoing enrollment.
Nvidia’s disclosed biotech stake is a supportive signal for GENB sentiment, but the article provides no incremental GENB-specific catalyst (no trial update, financing, or partnership terms).
GENB is positioned as receiving validation from a major AI/semiconductor investor, with a specific clinical-stage asset cited (GB-0895 in phase 3).
Clinical-program momentum plus a specific analyst price-target increase can improve risk appetite for the pipeline, especially around upcoming dosing milestones.
alphai scores every news story that mentions GENB with an AI model for sentiment and relevance, and aggregates insider trades from Generate Biomedicines, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Generate Biomedicines, Inc. (GENB) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ck0002100782-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Generate Biomedicines Inc. Reports Second Quarter 2026 Financial Results and Provides Business Update SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 studies for GB-0895 (anti-TSLP) in severe asthma continue to advance with recruit
6 min readNvidia (NVDA) said AI’s “most profound impact” will be in life sciences and announced an AI co-innovation lab with Eli Lilly, targeting up to $1 billion over five years. Nvidia’s May 13F showed it owned 833,000+ shares of Generate Biomedicines (GENB), valued at about $10.4 million as of Q1 end. The article links Nvidia’s AI push to its biotech investment.
7 min readNvidia, through its venture arm NVentures, owns 833,325 shares of Generate Biomedicines (NASDAQ: GENB), according to the article. The stake totals about $13 million, and Generate Biomedicines is a pre-profit biotech developing an AI platform for virtual drug testing; four candidates are in its pipeline, including one in Phase 3 for severe asthma (GB-0895). The piece cites estimates that drug development can take 10–15 years and about $2.6 billion per approved medicine.
6 min readReuters (May 27) reported Biohub, founded by Meta CEO Mark Zuckerberg and Priscilla Chan, developed an open-source global protein-biology model using fourth-generation evolutionary scale modeling (ESM) to speed drug discovery. Biohub said it will run via Biohub.ai and partners like AWS Bio Discovery, with computing credits, and expects broader lab use. The article also lists hedge-fund “AI drug discovery” holdings, including SOPHiA Genetics’ proposed MSK precision-oncology JV and Generate Biomed
6 min read
